SBT 020

Drug Profile

SBT 020

Alternative Names: SBT-020; SBT-020-01; SBT-20; SS 20 - Stealth BioTherapeutics; SS-20

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Stealth BioTherapeutics
  • Class Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Preclinical CNS disorders

Most Recent Events

  • 09 Jan 2017 Phase-II clinical trials in Huntington's disease (Early-stage disease) in Netherlands (SC) (EudraCT2016-003730-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top